Navigation Links
HER2 levels may aid in treatment selection for metastatic breast cancer
Date:12/2/2008

PHILADELPHIA Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.

Lapatinib, an oral chemotherapy agent, inhibits both HER2 and EGRF receptors, leaving unanswered questions about which patients are more likely to benefit. Researchers at the Norris Comprehensive Cancer Center found that HER2 amplification ("HER2-positive"), but not EGRF expression, is correlated with responsiveness to lapatinib. Women with both high and low levels of HER2 amplification respond to lapatinib. However, women with HER2-negative metastatic breast cancers do not respond.

Women with HER2-postitive metastatic breast cancer who receive lapatinib and chemotherapy have shown an improvement of approximately 50 percent in progression-free survival when compared to chemotherapy alone. Unfortunately, high volume laboratories using laboratory technicians instead of pathologists to score gene amplification misclassify approximately 10 percent of HER2 amplified breast cancers as not amplified, preventing these patients from being candidates for lapatinib.

"I would like to see all women with breast cancer tested appropriately, using the best method and certified personnel, to assess the HER2 status of their breast cancer so the appropriate treatment can be selected," said Michael Press, M.D., Ph.D., Norris Comprehensive Cancer Center Harold E. Lee Chair in Cancer Research and lead author of the study.

Currently lapatinib is approved by the FDA for use only in women who have HER2-positive metastatic breast cancer who were previously treated with anthracyclines, trastuzumab and taxane.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. High levels of prenatal smoking exposure affect sleep patterns in preterm neonates
2. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Give FDA Authority Over Tobacco Products
3. New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
4. Child-Care Relationships Tied to Kids Stress Levels
5. Men who take aspirin have significantly lower PSA levels
6. High-normal phosphate levels linked to early atherosclerosis
7. High Blood Fat Levels Tied to Ischemic Stroke Risk
8. Lipoprotein Levels May Predict Womens Hypertension Risk
9. Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications
10. REVISED AND UPDATED: Firearms Industry Statement on Results of CDC Blood Lead Levels in Hunters Study
11. Firearms Industry Statement on Results of CDC Blood Lead Levels in Hunters Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2017)... ... July 29, 2017 , ... Sunshine Coast ... treatment programs in British Columbia, Canada, is proud to announce it has achieved ... as a form of public outreach to showcase its innovative non-12 step methodology ...
(Date:7/28/2017)... ... July 28, 2017 , ... Mirror Mirror ... Crystal Rewards Program, the most successful CoolSculpting practices across the country are annually ... has achieved the coveted Diamond Level status, the highest ranking possible. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... The Military Family Initiative (MFI), ... announced the grant recipients of its inaugural community outreach grant program. , ... , Falcon’s Landing Chapter, Sterling, Va.: $5,000. Community Veterans Collaboration. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... The Aesthetic Surgery Center ... in the “2017 Best Plastic/Cosmetic Surgeon” category. Dr. Anurag Agarwal, Dr. Richard Maloney, ... The SWFL Choice Awards directly reflect the opinion of Florida residents and is sponsored ...
(Date:7/28/2017)... ... July 28, 2017 , ... Nominated ... Supply Chain Partners for 2017. MEBC received numerous client nominations from customers ... Brad Berger, SupplyChainBrain’s publisher, says “For 15 years running, SupplyChainBrain has published our ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... 2017  Endo International plc (NASDAQ: ENDP ... of its manufacturing network, the Company will be ceasing ... Huntsville, Alabama . The closure of ... next 12 to 18 months. The Huntsville ... of commoditized products and these restructuring actions are intended ...
(Date:7/20/2017)...  Prime Therapeutics LLC (Prime) released this statement from its ... Institute for Clinical and Economic Review,s (ICER) public meeting ... value of abuse-deterrent formulations (ADF) of opioids. Prime was the ... meeting. "The ICER ... the use of abuse-deterrent formulations (ADF) in opioids in terms ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
Breaking Medicine Technology: